A phase 2 dose-finding study of pegylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 12, 2005, Pages 2303-2310

  Furst, Daniel E ^a,c   Fleischmann, Roy ^a,b   Kopp, Elliott ^a   Schiff, Michael ^d   Edwards III, Carl K ^c   Solinger, Alan ^e   Macri, Michael ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RADIANT RESEARCH   (United States)

^c Denver Arthritis Clinic ^*  (United States)

^d Denver Arthritis Clinic   (United States)

^e AMGEN INC   (United States)

Author keywords

Rheumatoid arthritis; Tumor necrosis factor inhibitor clinical trial; Tumor necrosis factor receptor type I

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGSUNERCEPT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ARTHRITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 28844497898     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
3. [Erratum appears in N Engl J Med 1990;323:996].
4. Isomaki HA, Hakulinen T, Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chron Dis 1978;31:691-6.
5. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
6. Arend WPD, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33:305-15.
7. Arend WPD, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
8. Alsalameh S, Winter K, Al-Ward R, Wendler J, Kalden JR, Kinne RW. Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999;49:278-85.
9. Hale KK, Smith CG, Baker SL, et al. Multifunctional regulation of the biological effects of TNF-alpha by the soluble type I and type II TNF receptors. Cytokine 1995;7:26-38.
10. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
11. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-alpha. Arthritis Rheum 1993;36:1681-90.
12. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
13. [Erratum appears in Arthritis Rheum 2003;48:855].
14. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
15. Edwards CK III, Martin SW, Seely J, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315-36.
16. McComb J, Gould T, Chlipala E, et al. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis; correlation of plasma levels with efficacy. J Rheumatol 1999;26:1347-51.
17. Bendele A, McComb J, Gould T, et al. Combination benefit of PEGylated soluble tumor necrosis factor receptor type I (PEG s TNF-RI) and dexamethasone or indomethacin in adjuvant arthritic rats. Inflamm Res 1999;48:453-60.
18. Caldwell JR, Davis MW, Jelaca-Maxwell K, et al. A phase 1 study of PEGylated soluble tumor necrosis factor receptor type 1 (PEG sTNF-RI [p55]) in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1999;42 Suppl:S236.
19. Davis MW, Feige U, Bendele AM, Martin SW, Edwards CK. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000;59 Suppl 1:41-3.
20. Lubeck DP. Health-related quality of life measurements and studies in rheumatoid arthritis. Am J Manag Care 2002;8:811-20.
21. Redelmeier DA, Lorig K, Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993;153:1337-42.
22. World Health Organization. WHO adverse drug reaction terminology (WHO-ART). Uppsala, Sweden: Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Monitoring); 1977.
23. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.